January 23, 2019 8:14am

… While the oversold should flaunt their “stuff”

As US futures point to an upbeat open, after Tuesday’s sharp losses

Pre-open indication: 5 BUYs and 2 SELLs  

News: Athersys (ATHX) has pre-market news of summary results from its exploratory clinical study of the intravenous administration of MultiStem® cell therapy to treat patients who are suffering from acute respiratory distress syndrome (ARDS). The study results provide further confirmation of tolerability and a favorable safety profile associated with MultiStem treatment <read more> …

 

I answer one question, in which company should investors put, keep and commit their money!

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined and evaluated.

 

U.S. stock index futures are lookin’ good

Dow futures are UP +0.68% (+166 points) and NASDAQ futures are UP +0.50% (+34 points)

 

U.S. stock index futures fluctuated ahead of Wednesday's open, trying to shake off the negative trading seen in the previous session and in some international markets.

European stocks lower amid US-China trade talk uncertainty;

Asian markets were mixed, with stocks straddling between negative and positive territory for most of the day as uncertainty continues re trade talks

 

Data docket: mortgage applications are due out at 7 a.m. ET, followed by the Richmond Fed's survey of manufacturing activity at 10 a.m. ET.

 

Wednesday’s indications:

The iShares Nasdaq Biotechnology (IBB) is indicating a NEGATIVE -0.17% DOWNSIDE in the pre-market

The SPDR S&P Biotech ETF (XBI) is indicating a POSITIVE +0.54% UPSIDE

The Health Care Select Sector SPDR ETF (XLV) is NOT indicating

The iShares Russell 2000 (IWM) is indicating a POSITIVE +0.4% UPSIDE

 

Henry’omics:

Domestic politics i.e. shut down, political party unrest (squabbles) keeps the government resolute; triggering uncertainty across the U.S. yet the sector and market look for a REBOUND!

Tuesday’s evening post, “the CRISPR sold-off … the real question, how fast do they rebound after a free fall?”

I also stated, it also “Hammers home that economics move markets as an attention-grabbing headline kills the sector but, that wasn’t the whole story – weakness and confidence was evident after a market holiday. Volatility and short-termism still rule the sector!”

 

Tuesday’s night’s percentage (%) indicators:  thin

  • Review the range of the 7 upside from +0.37% (ADRO) to +8.84% (MDXG +$0.22) while the 36 downside ranged from -0.47% (SLDB) to -19.85% (EDIT) with 2 flat closes (BSTG and RENE.L).

Volume was low and increasing

  • 2 out of the 7 upside had higher (than the 3 month average) volume
  • 18 out of the 36 downside experienced greater volume (than the 3 month average) volume

Running the month:

In 14 sessions in January – there was 9 positive closes, 1 holiday and 5 negative closes – so far!

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Athersys (ATHX) closed down -$0.04 to $1.39 but, has pre-market news of summary results from its exploratory clinical study of the intravenous administration of MultiStem® cell therapy to treat patients who are suffering from acute respiratory distress syndrome (ARDS). The study results provide further confirmation of tolerability and a favorable safety profile associated with MultiStem treatment. Importantly, MultiStem treatment was associated with lower mortality and a greater number of ventilator-free and intensive care unit (ICU) free days in the first month following diagnosis relative to patients receiving placebo. Furthermore, analysis of initial biomarker data reflects lower levels of inflammatory markers/cytokines following MultiStem treatment, an expected mechanism of action in this patient population – BUY;

Caladrius Bioscience (CLBS) closed down -$0.37 to $4.71 and has a negative -$0.01 or -0.21% aftermarket indication. The investor letter says many things about the past – they would NOT have the cash because PCT (a NeoStem multi-year investment) since sold to Hitachi yet, slips some truths re their present (a BIG bet on a Shire platform disposal) and their future – one of the BIG issues is their “runway” – 18 months with a $20 M “spend”; so an offering will be in the future if they have significant regulatory results. NOT a fan - SELL;

Cellectis (CLLS) closed down -$0.86 to $15.88 and has an positive +$0.14 or +0.85% aftermarket indication – BUY;

CRISPRS Therapeutics (CRSP) closed down -$4.05 to $33.0-8 after Friday’s +$1.25 to $37.13. The pre-market indication is a negative -$0.64 or -1.95% – Maintaining SELL;

Editas Medicine (EDIT) closed down -$5.19 to $20.95 after news of their CEOs resignation following  Friday’s  -$0.07 to $26.14 after Thursday’s -$0.13 to $26.21 and last Wednesday’s -$0.14 to $26.26 a. There is a positive +$0.34 or +1.62% pre-market indication – the phoenix rises from Tuesday’s ashes - BUY;

Intellia Therapeutics (NTLA) closed down -$1.04 to $14.16 after Friday’s +$0.28 to $15.20 after Thursday’s -$0.10 to $14.92 and last Wednesday’s +$0.77 to $15.02. There is a positive +$0.84 or +5.93% aftermarket indication – BUY;

uniQure (QURE) closed down -$0.22 to $31.14 after Friday’s +$0.13 to $31.36. QURE starts a short week with the U.S. FDA has completed its review of an IND application for AMT-130, and the IND is now effective allowing uniQure to begin its planned P1/2 study.  AMT-130 comprises a recombinant AAV5 vector carrying a DNA cassette encoding a micro-RNA that non-selectively lowers or knocks-down human huntingtin protein in Huntington’s disease patients. There is a positive +$0.25 or +0.80% aftermarket indication – Maintaining BUY;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.